All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: driver lesion dependent effects on leukemic stem cells

Acute myeloid leukemia (AML) is an aggressive, often fatal hematopoietic malignancy. All-trans retinoic acid (atRA), one of the first molecularly targeted drugs in oncology, has greatly improved the outcome of a subtype of AML, acute promyelocytic leukemia (APL). In contrast, atRA has so far provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Chi H., Grandits, Alexander M., Purton, Louise E., Sill, Heinz, Wieser, Rotraud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644151/
https://www.ncbi.nlm.nih.gov/pubmed/32900260
http://dx.doi.org/10.1080/15384101.2020.1810402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644151/
https://www.ncbi.nlm.nih.gov/pubmed/32900260
http://dx.doi.org/10.1080/15384101.2020.1810402

Ejemplares similares